Search

Search Constraints

You searched for: Author/Creator Jang, Ming-Kuei

Search Results

1. IC‐P‐082: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION. (1st July 2006)

2. IC‐P‐179: IN VIVO TRACKING OF TAU PATHOLOGIES WITH 18F‐PM‐PBB3 (18F‐APN‐1607) PET IN AD AND DIVERSE NON‐AD TAUOPATHIES. (1st July 2019)

3. IC‐P‐217: PRECLINICAL AND CLINICAL CHARACTERIZATION OF 18F‐PM‐PBB3, A PET LIGAND FOR DIVERSE TAU PATHOLOGIES. (1st July 2006)

4. P1‐125: PRECLINICAL AND CLINICAL CHARACTERIZATION OF 18F‐PM‐PBB3, A PET LIGAND FOR DIVERSE TAU PATHOLOGIES. (1st July 2006)

5. P1‐400: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION. (1st July 2006)

6. P2‐382: IN VIVO TRACKING OF TAU PATHOLOGIES WITH 18F‐PM‐PBB3 (18F‐APN‐1607) PET IN AD AND DIVERSE NON‐AD TAUOPATHIES. (1st July 2019)

8. P4‐037: APRINOIA THERAPEUTIC'S SMALL MOLECULE DISCOVERY PLATFORM: USING [18F]‐APN‐1607 FOR TARGET ENGAGEMENT STUDIES WITH SMALL MOLECULE THERAPEUTICS. (1st July 2019)

9. The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease. (October 2020)